Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine* * Data presented in part at the May 2000 New Orleans meeting of the American Society of Clinical Oncology
Titel:
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin–vindesine* * Data presented in part at the May 2000 New Orleans meeting of the American Society of Clinical Oncology